Nevertheless, small-molecule CDK8/19 inhibitors did show beneficial therapeutic effects in colon cancer models but these effects were observed only in vivo and specifically when targeting metastatic growth of colon cancers in the liver [3]. This evidence concerns the gene CDK8 and colonic neoplasm.